Posted by Michael Wonder on 24 Jun 2019
How big pharma suppresses ‘biosimilars’
23 June 2019 - Deals with insurers and pharmacy benefit managers at patient and taxpayer expense.
Biologic drugs—pharmaceuticals produced from living organisms—are at the forefront of medical innovation and hold tremendous potential to improve and save lives. Unfortunately, their pricing has been a driver of rapidly escalating, unsustainable drug costs.
Congress recognised the need for competition to slow price growth, and in 2010 passed the Biologics Price Competition and Innovation Act.
